Radiation Therapy for Wilms Tumor | NYU Langone Health
NYU Langone doctors sometimes use low-dose radiation therapy to treat children who have a Wilms tumor.
Radioactive Iodine Ablation for Hyperthyroidism | NYU Langone Health
NYU Langone endocrinologists may use radioactive iodine ablation to treat hyperthyroidism.
Radioactive Iodine Therapy for Thyroid Nodules & Cancers | NYU Langone Health
NYU Langone doctors may use radioactive iodine therapy to manage some toxic nodules and thyroid cancers.
Radiofrequency Ablation for Neck Pain | NYU Langone Health
Doctors at NYU Langone may recommend radiofrequency ablation to relieve neck pain.
Radiosurgery & Radiation Therapy for Pituitary Tumors | NYU Langone Health
NYU Langone doctors may use radiosurgery or radiation therapy to manage some pituitary tumors.
Randomized Clinical Evaluation of the AccuCinch Ventricular Restoration System in Patients who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
The purpose of this research study is to assess the safety and effectiveness of the AccuCinch Ventricular Restoration System and compare it to standardized heart failure medications.The AccuCinch Ventricular Restoration System is an investigational (experimental) device intended to treat patients who are experiencing symptoms of heart failure due to a dilated left ventricle (heart chamber that pumps blood).
Randomized Controlled Open-Label Parallel Group Multi-Center Prospective Phase 4 Study Comparing the Efficacy of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2 3 and 4 Pressure Injuries
This post-marketing study is being performed to assess the effectiveness of Altrazeal® Transforming Powder Dressing (“Altrazeal®” or “TPD”) manufactured by ULURU Inc. in patients with pressure injuries (sometimes also referred to as pressure sores or decubitus ulcers) compared to the current Standard of Care (SOC) therapies. TPD is manufactured, marketed, and used in the United States of America (US). ULURU Inc. is registered with the US Food and Drug Administration (FDA) and Altrazeal® is listed as a Class I 510(k) exempt medical device: “dressing, wound, hydrogel without drug and/or biologic.” (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=410757&lpcd=NAE) Under the supervision of a health care professional, TPD may be used in surgical, acute or chronic wounds including pressure injuries.Objectives:Primary: To compare the efficacy of TPD in reducing primary dressing changes in the treatment of non-infected Stage 2, 3 and 4 pressure injuries (PrIs).Secondary: Evaluate: 1) wound healing trajectories2) safety in the form of adverse events3) subject pain for sensate patientsExploratory: Evaluate: 1) resource utilization of TPD relative to SOC2) cost-effectiveness of TPD versus SOC3) budget impact analysis of adopting TPD4) wound quality of life5) research subject satisfaction6) other ad-hoc analyses as warranted
Randomized Double-blind Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Safety Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in adult subjects diagnosed with FOSs who are taking 1 to 3 ASMs. Eligible subjects will be randomized 1:1:1 (XEN1101 25 mg: 15 mg: placebo) and stratified according to use of background CYP 3A4-inducer ASMs.
RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY OF VE202 IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS
VE202 is a rationally designed, live biotherapeutic product (LBP) for oral (po) administration that consists of 16 well-characterized, clonally-derived, nonpathogenic, nontoxigenic, commensal strains of Clostridia species. VE202 includes 12 strains from Clostridium cluster XIVa, 2 strains from cluster IV, and 2 strains from cluster XVIII. These bacteria, which were originally derived from the stool of a single healthy human, are obligate anaerobes that were selected for inclusion in the LBP based on individual strain- and consortia-specific properties that include association with healthy human gut microbiomes, promotion of colonic regulatory T (Treg) cells, production of beneficial and immunoregulatory metabolites, and lack of overt pathogenic or toxigenic features. The goal of treatment with VE202 is to restore the gut microbiome to a healthy and anti-inflammatory state in patients with UC via induction of immunoregulatory cells in the intestine, production of epithelium-protective metabolites, suppression of potentially inflammatory organisms, and maintenance of homeostatic signaling.
Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants with Cholestatic Pruritus (EXPAND)
The purpose of this clinical research study is to learn more about the use of the study drug, maralixibat, for the treatment of cholestatic pruritus (itch due to liver disease).